Disruptive Dose with Eric McCulley

Head of Portfolio Innovation, US Immunology, UCB

In this DHCG Disruptive Dose, Mark Bard speaks with Eric McCulley, Head of Portfolio, US Immunology at UCB, about why the most important question in pharma innovation isn’t what technology to adopt — it’s whether that technology is genuinely serving patients and HCPs. Drawing on his background as a bedside nurse, Eric makes the case for starting with the patient first, closing care gaps over click gaps, and letting brand growth follow from doing what’s right.